|
Feb 15
|
AstraZeneca: IMFINZI improved event-free survival, OS across MIBC
|
|
Feb 15
|
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
|
|
Feb 14
|
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
|
|
Feb 14
|
Is AstraZeneca PLC (AZN) the Best Foreign Dividend Stock to Buy According to Analysts?
|
|
Feb 12
|
3 UK Stocks That May Be Undervalued Based On Current Estimates
|
|
Feb 12
|
AstraZeneca PLC (AZN): Among the Best International Dividend Stocks to Buy Now
|
|
Feb 11
|
Is AstraZeneca PLC (AZN) the Safest Dividend Stock in the UK?
|
|
Oct 12
|
AstraZeneca PLC (AZN): A Top Holding in George Soros’s Portfolio
|
|
Oct 9
|
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Oct 8
|
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
|
|
Oct 8
|
Health Care Roundup: Market Talk
|
|
Oct 8
|
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
|
|
Oct 8
|
AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint
|
|
Oct 8
|
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
|
|
Oct 7
|
5 Large Drug Stocks to Watch From a Thriving Industry
|
|
Oct 7
|
AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
|
|
Oct 7
|
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
|
|
Oct 7
|
AstraZeneca and Gilead Sciences merger would be the biggest in the pharma history
|
|
Aug 30
|
QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases
|
|
Aug 29
|
Why Is Merck (MRK) Up 3.8% Since Last Earnings Report?
|